Construction of bispecific nanobodies To construct the PV2-PV3 recombinant fusion nanobody, a 15-amino acid flexible linker (GGGGS) 3 was selected as the connecting peptide
Spreading doses across the week mimics the body's natural pulsatile hormone release better than infrequent large injections
Second, targeting eryptosis pathways offers new therapeutic opportunities: strategies to mitigate eryptosis could include optimizing clearance of eryptosis-inducing uremic toxins via advanced dialysis modalities (e.g., hemodialysis combined with hemadsorption [HA + HD] for protein-bound uremic toxins) or novel pharmacotherapies, such as inhibitors of Organic Anion Transporter 2 (OAT2) to block indoxyl sulfate uptake by erythrocytes, antioxidants (e.g., N-acetyl-L-cysteine, vitamin E) to counteract oxidative stress-mediated eryptosis, or modulators of Ca 2+ signaling (e.g., NO donors) to stabilize erythrocyte membrane asymmetry
Berberine's effects on mitochondrial function and metabolic efficiency could theoretically complement this
The timing discipline achieved nothing because the peptide degraded before administration
In contrast, standard BPC-157 may degrade when taken orally
